Health

According to Bharat Biotech, the vaccine is 93.4% effective against severe Covid-19, Health News and ET Health World.

A phase III trial of covaxin conducted by Hyderabad’s Barrat Biotech showed that it was 93.4% effective against severe symptomatic Covid-19, the company said Saturday.

The data showed 65.2% protection against the Delta variant first identified in India.

Delta variants caused a surge in infectious diseases in April and May, resulting in the highest daily deaths in the world.

In addition, the study showed 77.8% efficacy against symptomatic Covid-19.

Last month, vaccine maker AstraZeneca quoted the study, stating that the vaccine was effective against Delta and Kappa variants.

The country is receiving the AstraZeneca vaccine produced domestically by the Serum Institute of India and plans to increase its monthly production from July to nearly 100 million doses.

Bharat Biotech currently estimates that it will administer 23 million doses per month.

Phase III data was obtained when Ocugen Inc, co-developing Covaxin with Bharat Biotech for the US market, is preparing to seek full approval in the US.

India, with 30.45 million infections, is the second most affected country after the United States, with 33 million. The death toll in South Asian countries now exceeds 400,000.



According to Bharat Biotech, the vaccine is 93.4% effective against severe Covid-19, Health News and ET Health World.

Source link According to Bharat Biotech, the vaccine is 93.4% effective against severe Covid-19, Health News and ET Health World.

Related Articles

Back to top button